Novavax(US:NVAX)2026-01-12 13:01Financial Updates - Novavax, Inc. plans to provide an update for investors on January 12, 2026, regarding its financial results for the year ended December 31, 2025[6]. - The preliminary financial data for 2025 is subject to change and has not been audited by Ernst & Young LLP, indicating potential material differences from actual results[7]. - The financial results and updates are crucial for investors and will be detailed in the full financial statements prepared in accordance with U.S. GAAP[7]. - The company has not disclosed specific financial metrics or performance indicators in this report[6]. Investor Presentations - The company will present at the 44th Annual J.P. Morgan Healthcare Conference, sharing strategic and business updates[9]. - Forward-looking statements in the investor presentation will highlight anticipated financial results and operational expectations for 2025, 2026, and 2027[8]. - The investor presentation will be accessible on Novavax's website under "Latest Investor Presentation"[9]. Risks and Uncertainties - The company emphasizes that actual results may differ materially from forward-looking statements due to various risks and uncertainties[8]. - The report includes a cautionary note regarding the reliance on preliminary financial data and forward-looking statements[10]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[5].